Zymeworks (ZYME) FCF Margin (2021 - 2026)
Zymeworks (ZYME) posted FCF Margin of 1902.74% for Q1 2026, down 341.46% sequentially from 431.01% in Q4 2025, and down 189011.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Zymeworks (ZYME) FCF Margin (2021 - 2026) Analysis & Trends
Zymeworks has reported FCF Margin for 6 years, with the latest figure at 1902.74% in Q1 2026.
- Quarterly FCF Margin fell 189011.0% year-over-year to 1902.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 94.66% (down 1135.0% YoY) and the FY2025 annual result came in at 32.58%, up 11426.0% from the prior year.
- FCF Margin retreated to 1902.74% in Q1 2026 per ZYME's latest filing, from 431.01% in the prior quarter.
- Over five years, FCF Margin peaked at 100.87% in Q4 2022 and troughed at 3109.08% in Q1 2022.
- A 5-year average of 603.96% and a median of 134.78% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2026: FCF Margin soared 287417 bps in 2023, then sank 189011 bps in 2026.
- Over 5 years, FCF Margin stood at 100.87% in 2022, then slipped by 7 bps to 94.11% in 2023, then plunged by 243 bps to 134.78% in 2024, then sank by 220 bps to 431.01% in 2025, then slumped by 341 bps to 1902.74% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1902.74%, 431.01%, and 115.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | -696.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -696.03% |
| Mar 31, 2026 | -1,907.56% |
| Dec 31, 2025 | -431.01% |
| Sep 30, 2025 | -115.24% |
| Jun 30, 2025 | 23.86% |
| Mar 31, 2025 | -12.87% |
| Dec 31, 2024 | -134.78% |
| Sep 30, 2024 | -42.37% |
| Jun 30, 2024 | -132.96% |
| Mar 31, 2024 | -377.47% |
| Dec 31, 2023 | 80.21% |
| Sep 30, 2023 | -264.13% |
| Jun 30, 2023 | -102.84% |
| Mar 31, 2023 | -234.91% |
| Dec 31, 2022 | 100.62% |
| Sep 30, 2022 | -2,812.47% |
| Jun 30, 2022 | -1,056.36% |
| Mar 31, 2022 | -3,109.08% |
| Dec 31, 2021 | -691.15% |